Healthcare data and technology are intertwined, and the regulatory framework governing the medicines regulation is looking to update the regulations to bring them in tune with the use of new technologies and access to new platforms for handling healthcare data in real time.
This whitepaper looks at the roles of AI applications and Real World Evidence in the pharma industry and how both can be leveraged while devising successful global regulatory strategies, including:
- The role of AI in collecting and storage of data - is it being accepted globally?
- AI in pharmacovigilance (handling structured and unstructured datasets)
- Improving safety and risk management
- Real World Evidence and defining its quality
- Initiatives to incorporate RWD into regulatory decision making
- The challenges in using AI in the healthcare industry
To download, simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. Have any questions or interested in sponsoring future content? Email andrew.burrows@informa.com.
This piece represents the views of the author and not necessarily the views of Informa Connect Life Sciences or the Global Pharmaceutical Regulatory Affairs Summit.
Log in or Create an Informa Connect Account to Access this content
Creating an account also means you'll get special access to article updates and exclusive industry content.